Patents by Inventor Andre Engling

Andre Engling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USES OF IMMUNOCONJUGATES TARGETING CD138
    Publication number: 20190117770
    Abstract: Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.
    Type: Application
    Filed: September 24, 2018
    Publication date: April 25, 2019
    Applicants: Biotest AG, ImmunoGen, Inc.
    Inventors: Gregor Schulz, Frank Osterroth, Thomas Haeder, Christoph Bruecher, Gabriele Niemann, Andre Engling, Christoph Uherek, Benjamin Daelken, Andrea Wartenberg-Demand, Chantal Zuber, Marcus Gutscher, Katrin Bernoester, Martin Koenig
  • Uses of immunoconjugates targeting CD138
    Patent number: 10117932
    Abstract: Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: November 6, 2018
    Assignees: BIOTEST AG, IMMUNOGEN INC.
    Inventors: Gregor Schulz, Frank Osterroth, Thomas Haeder, Christoph Bruecher, Gabriele Niemann, Andre Engling, Christoph Uherek, Benjamin Daelken, Andrea Wartenberg-Demand, Chantal Zuber, Marcus Gutscher, Katrin Bernoester, Martin Koenig
  • Uses of immunoconjugates targeting CD138
    Patent number: 9289509
    Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: March 22, 2016
    Assignees: Biotest AG, Immunogen Inc.
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng, Gregor Schulz
  • USES OF IMMUNOCONJUGATES TARGETING CD138
    Publication number: 20140010828
    Abstract: Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.
    Type: Application
    Filed: December 7, 2012
    Publication date: January 9, 2014
    Applicants: IMMUNOGEN, INC., BIOTEST AG
    Inventors: Gregor Schulz, Frank Osterroth, Thomas Haeder, Christoph Bruecher, Gabriele Niemann, Andre Engling, Christoph Uherek, Benjamin Daelken, Andrea Wartenberg-Demand, Chantal Zuber, Marcus Gutscher, Katrin Bernoester, Martin Koenig
  • USES OF IMMUNOCONJUGATES TARGETING CD138
    Publication number: 20110123554
    Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.
    Type: Application
    Filed: May 5, 2010
    Publication date: May 26, 2011
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng